- Home
- RYTM
as 05-22-2025 4:00pm EST
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 3.8B | IPO Year: | 2017 |
| Target Price: | $75.42 | AVG Volume (30 days): | 616.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.17 - $68.58 | Next Earning Date: | 05-07-2025 |
| Revenue: | $136,863,000 | Revenue Growth: | 48.88% |
| Revenue Growth (this year): | 37.88% | Revenue Growth (next year): | 72.84% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mazabraud Yann | RYTM | EVP, Head of International | Apr 29 '25 | Sell | $65.08 | 6,745 | $438,946.39 | 37,655 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Apr 29 '25 | Sell | $65.09 | 7,031 | $457,663.26 | 19,209 | |
| Mazabraud Yann | RYTM | EVP, Head of International | Apr 8 '25 | Sell | $60.96 | 17,750 | $1,082,497.31 | 37,655 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Apr 8 '25 | Sell | $59.84 | 20,760 | $1,248,490.37 | 19,209 | |
| German Christopher Paul | RYTM | Corporate Controller & CAO | Mar 20 '25 | Sell | $54.23 | 344 | $18,655.12 | 2,889 | |
| Mazabraud Yann | RYTM | EVP, Head of International | Mar 14 '25 | Sell | $51.26 | 75,000 | $3,861,272.37 | 37,655 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
GuruFocus.com
15 days ago
Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...
Zacks
15 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
MT Newswires
15 days ago
Rhythm Pharmaceuticals' Q1 Net Loss Narrows, Revenue Increases
GlobeNewswire
15 days ago
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
GlobeNewswire
16 days ago
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
MT Newswires
21 days ago
Rhythm Pharmaceuticals Insider Sold Shares Worth $438,946, According to a Recent SEC Filing
MT Newswires
21 days ago
Rhythm Pharmaceuticals Insider Sold Shares Worth $457,663, According to a Recent SEC Filing
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.